脑膜瘤免疫微环境随生物学状态演变
研究利用多种技术绘制2727例脑膜瘤免疫微环境图谱,发现其免疫浸润丰富、以巨噬细胞为主,且随肿瘤进展向免疫抑制表型演变;离体模型显示STING激动与抗PD-1联合具有协同效应。
要点
- 脑膜瘤免疫浸润在34种人类癌症中位居前列,以巨噬细胞为主。
- 侵袭性脑膜瘤具有更早期阶段、免疫抑制的免疫细胞和增殖性肿瘤细胞。
- STING激活联合PD-1阻断在离体脑膜瘤模型中显示协同细胞因子释放。
核心结论
- 脑膜瘤微环境具有丰富免疫浸润且随生物学状态演变,为合理治疗建模和策略开发提供框架。
研究设计与样本
- 对2727例脑膜瘤采用正交方法分析免疫微环境,包括24例质谱流式、24例单细胞RNA测序、1437例bulk RNA测序、1125例DNA甲基化、117例多重免疫荧光,以及5例配对外周血样本和10例人脑膜。
- 建立患者来源器官型肿瘤球(PDOTS)以评估STING刺激联合抗PD-1治疗的效果。
主要发现
- 脑膜瘤显示丰富免疫浸润,在34种人类癌症类型(n=12188)中位居最高之列。
- 巨噬细胞在脑膜瘤微环境中占主导,与外周血的淋巴主导形成对比,脑膜呈现介于脑膜瘤和外周血之间的免疫特征。
- 免疫细胞和肿瘤细胞的细胞状态与表型随肿瘤进展而转变,侵袭性脑膜瘤具有更早期阶段、免疫抑制的免疫细胞和增殖性肿瘤细胞。
- 离体脑膜瘤PDOTS显示对STING激活的诱导反应,以细胞因子释放升高为标志,与PD-1阻断联合时具有协同作用。
临床怎么用
- 脑膜瘤免疫微环境图谱可作为资源,指导基于免疫微环境特征的理性治疗建模和策略开发。
- STING激活联合PD-1阻断在离体模型中显示协同效应,提示潜在治疗方向,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mechanisms driving aggressive meningiomas remain poorly understood. Given the pivotal role of the immune microenvironment in tumor progression, we developed a comprehensive atlas of the meningioma microenvironment, with a view toward identifying modifiable opportunities. METHODS: The immune microenvironment of 2,727 meningiomas was profiled using orthogonal methodologies, including 24 with mass cytometry, 24 single-cell RNAseq, 1,437 bulk RNAseq, 1,125 DNA methylation, 117 multiplex immunofluorescence, as well as that of 5 paired peripheral blood samples and 10 human meninges. Patient-derived organotypic tumor spheroids (PDOTS) were established to assess the effect of STING stimulation combined with anti-PD-1 treatment. RESULTS: We revealed a rich immune infiltration in meningioma, among the highest across 34 human cancer types (n = 12,188). Macrophages predominated in meningioma microenvironment, in contrast to the lymphoid dominance of peripheral blood, with meninges exhibiting an intermediate immune profile between meningiomas and peripheral blood. Cellular states and phenotypes of both immune and tumor cells shifted during tumor progression, with aggressive meningiomas possessing earlier-stage, immunosuppressive immune cells and proliferative tumor cells. Using ex vivo meningioma PDOTS, we demonstrated inducible responses to STING activation, marked by elevated cytokine release, which were synergistic when combined with PD-1 blockade. CONCLUSIONS: These findings offer an extensive resource on the cellular heterogeneity of the meningioma microenvironment and provide a framework for rational therapeutic modeling and strategy development.
引用
- Guo X, Moynihan ZA, Driver J, et al. Meningioma microenvironment harbors a rich immune landscape that evolves with biological state. Neuro Oncol. 2026. PMID: 41630100. doi:10.1093/neuonc/noag022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。